Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024GlobeNewsWire • 05/22/24
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024GlobeNewsWire • 04/29/24
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsGlobeNewsWire • 03/27/24
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 02/28/24
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024GlobeNewsWire • 02/21/24
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19GlobeNewsWire • 01/08/24
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023GlobeNewsWire • 11/13/23
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/08/23
Atea Pharmaceuticals Announces Participation at Upcoming Investor ConferencesGlobeNewsWire • 11/08/23
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023GlobeNewsWire • 11/01/23
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewsWire • 09/06/23
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/08/23
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023GlobeNewsWire • 08/01/23
Atea Pharmaceuticals' Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra BiosciencesGlobeNewsWire • 05/30/23
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra BiosciencesGlobeNewsWire • 05/23/23
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/08/23
Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023GlobeNewsWire • 05/01/23
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19GlobeNewsWire • 04/25/23